타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap) Regeneron / Bayer·VEGF-A / VEGF-B / PIGF 244 trials | voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl) Spark Therapeutics / Roche·RPE65 (AAV2) 7 trials | |||
|---|---|---|---|---|---|
Overview Program | Eylea (aflibercept) | Lucentis (ranibizumab) | Vabysmo (faricimab) | Luxturna (voretigene neparvovec) | Triamcinolone |
Overview Company | Regeneron / Bayer | Roche / Genentech | Roche / Genentech | Spark Therapeutics / Roche | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | CGT | ANTIBODY |
Overview Target | VEGF-A / VEGF-B / PIGF | VEGF-A | Ang-2 / VEGF-A | RPE65 (AAV2) | Diabetic Macular Edema |
Overview Indication | Wet AMD, DME, RVO, diabetic retinopathy | Wet AMD, DME, RVO, myopic CNV | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion | Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Approved (flag incomplete) |
Positioning Key differentiator | unique records | Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1 | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. | Surgical subretinal delivery; landmark ophthalmology gene therapy | — |
Positioning Known limitation | Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients. | Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents. | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. | bypasses defective phototransduction pathways, showing promise for patients regardless of their genetic profile | — |
Positioning Development positioning | — | — | 1L anti-VEGF alternative | — | — |
Technology Vector | — | — | — | AAV2 | — |
MoA Mechanism | Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina. | Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema. | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. | Voretigene neparvovec uses AAV2 to deliver functional RPE65 to retinal pigment epithelium, restoring the visual cycle and improving light sensitivity in RPE65-mutant IRD. | targeting of STING-TBK1 signaling |
MoA Biomarker | biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra | biomarker of treatment response, supporting further validation in larger independent cohorts | OCT central subfield thickness, BCVA, presence of intraretinal fluid. | MLMT, FST, BCVA. | biomarkers have shown that both TA and DEX implant are effective in promoting scattered punctate and plaque-l |
Toxicology Species | Cynomolgus monkey | — | — | NHP, Dog | — |
Toxicology Animal (cat.) | NHP | — | — | NHP, Dog | — |
Toxicology Major finding | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. | Procedure-related ocular AEs; inflammation manageable with steroids | — |
Toxicology CRS | N/A | N/A | N/A | — | — |
Clinical Safety signal | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. | Procedure-related ocular AEs; inflammation manageable with steroids | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | 4 recruiting · 3 completed | No active/completed counts |
Preclinical Animal (cat.) | — | — | Rat | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap) Regeneron / Bayer·VEGF-A / VEGF-B / PIGF 244 trials | voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl) Spark Therapeutics / Roche·RPE65 (AAV2) 7 trials | |||
|---|---|---|---|---|---|
Overview Program | Eylea (aflibercept) | Lucentis (ranibizumab) | Vabysmo (faricimab) | Luxturna (voretigene neparvovec) | Triamcinolone |
Overview Company | Regeneron / Bayer | Roche / Genentech | Roche / Genentech | Spark Therapeutics / Roche | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | CGT | ANTIBODY |
Overview Target | VEGF-A / VEGF-B / PIGF | VEGF-A | Ang-2 / VEGF-A | RPE65 (AAV2) | Diabetic Macular Edema |
Overview Indication | Wet AMD, DME, RVO, diabetic retinopathy | Wet AMD, DME, RVO, myopic CNV | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion | Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | Approved (flag incomplete) |
Positioning Key differentiator | unique records | Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1 | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. | Surgical subretinal delivery; landmark ophthalmology gene therapy | — |
Positioning Known limitation | Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients. | Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents. | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. | bypasses defective phototransduction pathways, showing promise for patients regardless of their genetic profile | — |
Positioning Development positioning | — | — | 1L anti-VEGF alternative | — | — |
Technology Vector | — | — | — | AAV2 | — |
MoA Mechanism | Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina. | Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema. | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. | Voretigene neparvovec uses AAV2 to deliver functional RPE65 to retinal pigment epithelium, restoring the visual cycle and improving light sensitivity in RPE65-mutant IRD. | targeting of STING-TBK1 signaling |
MoA Biomarker | biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra | biomarker of treatment response, supporting further validation in larger independent cohorts | OCT central subfield thickness, BCVA, presence of intraretinal fluid. | MLMT, FST, BCVA. | biomarkers have shown that both TA and DEX implant are effective in promoting scattered punctate and plaque-l |
Toxicology Species | Cynomolgus monkey | — | — | NHP, Dog | — |
Toxicology Animal (cat.) | NHP | — | — | NHP, Dog | — |
Toxicology Major finding | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. | Procedure-related ocular AEs; inflammation manageable with steroids | — |
Toxicology CRS | N/A | N/A | N/A | — | — |
Clinical Safety signal | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. | Procedure-related ocular AEs; inflammation manageable with steroids | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | 4 recruiting · 3 completed | No active/completed counts |
Preclinical Animal (cat.) | — | — | Rat | — | — |
추천 비교
추천 비교